Background. We evaluated the annual rate of fi brosis progression in chronic hepatitis B and C patients with elevated alanine aminotransferase (ALT) levels. Methods. Forty-nine chronic hepatitis B patients and 21 chronic hepatitis C patients, each of whom had undergone two or more liver biopsies at an interval of more than 1 year, were enrolled in this retrospective clinical research protocol. The annual rate of fi brosis progression was calculated by dividing the change in fi brosis stage between the fi rst and second liver biopsies by the interval in years between them. Results. The median interval in chronic hepatitis B and C was 3.4 (fi rst and third quartiles, 1.8-4.7) and 3.2 (2.1-6.5) years, respectively. Overall, the mean fi brosis progression rate was 0.21 ± 0.31 (mean ± SD) fi brosis units (FU) per year in 49 patients with chronic hepatitis B, and 0.13 ± 0.18 FU/year in 21 patients with chronic hepatitis C. The ALT level was an independent variable correlating with fi brosis progression. In patients whose median ALT level was 70 IU/l or more, the mean fi brosis progression rate was 0.28 ± 0.32 FU/year in 36 patients with chronic hepatitis B, and 0.22 ± 0.23 FU/year in eight patients with chronic hepatitis C. Conclusion. This paired-biopsy study of untreated chronic hepatitis B or C demonstrated that fi brosis progression occurred largely in patients with continuously elevated ALT levels even over a relatively short period, and that liver fi brosis might progress by one stage within an average of 4-5 years of follow-up in patients with elevated ALT of 70 IU/l or more.
Introduction
Chronic hepatitis B and chronic hepatitis C are progressive diseases linked to the development of cirrhosis and hepatocellular carcinoma. [1] [2] [3] [4] [5] [6] [7] [8] The progression from mild chronic hepatitis to cirrhosis is evaluated by histological examination and is expressed in terms of the stage of liver fi brosis. [1] [2] [3] [4] [5] [6] [7] [8] [9] Cirrhosis may take many decades to develop, and the progression to cirrhosis varies markedly among patients with chronic hepatitis B 1,3,13,14 or C. 6, 7, 15, 16 The progression of liver fi brosis has been extensively studied in patients with chronic hepatitis C. The rate of fi brosis progression is generally expressed as annual progression or regression of fi brosis, and is calculated by dividing the fi brosis stage at the fi rst biopsy by the interval between the presumed date of contamination and the date of the fi rst biopsy, [17] [18] [19] [20] or by dividing the difference in fi brosis stage between the fi rst and second liver biopsies by the time interval between them. [21] [22] [23] By use of these systems, the rate of fi brosis progression in chronic hepatitis C has been reported to be from 0.10 to 0.15 fi brosis units per year. [17] [18] [19] [20] [21] [22] [23] In contrast to chronic hepatitis C, in chronic hepatitis B the rate of fi brosis progression has not been sufficiently studied even though histological examination makes use of the same criteria. Diffi culties in defi ning the rate of fi brosis progression in chronic hepatitis B include the complex and variable spectrum of chronic hepatitis B virus (HBV) infection, and the heterogeneity of the disease progression as a result of hepatic infl ammation and subsequent fi brosis. [24] [25] [26] Nevertheless, understanding the progression of fi brosis in chronic hepatitis B is the basis of disease management and longterm prognosis. In this study, we aimed to evaluate the annual rate of fi brosis progression in chronic hepatitis B and C patients with elevated alanine aminotransferase (ALT) levels.
Patients and methods

Patients
Between January 1980 and December 2002, 2125 consecutive patients underwent peritoneoscopic liver biopsy at Okayama University Hospital. These patients were registered in a peritoneoscopic liver fi brosis database approved by the Okayama University ethics committee. From this database we extracted data on 298 patients who had undergone two or more liver biopsies. Of them, 77 were excluded for the following reasons: liver diseases other than chronic hepatitis B or C; coinfection with HBV and hepatitis C virus (HCV); chronic hepatitis B or C combined with other conditions such as autoimmune hepatitis, hemochromatosis, idiopathic portal hypertension, or hepatocellular carcinoma; or the second biopsy was performed within 1 year of the fi rst. Also excluded were 154 patients who had received any kind of antiviral or immunomodulatory therapy, including interferon or corticosteroids, between biopsies. Finally, to investigate the outcomes, 49 patients with chronic hepatitis B and 21 with chronic hepatitis C, each of whom had undergone two or more liver biopsies at an interval of more than 1 year, were enrolled in this retrospective clinical research protocol. The clinical characteristics and laboratory data collected within 2 weeks before each liver biopsy were retrieved from the peritoneoscopic liver biopsy database.
A diagnosis of chronic hepatitis B was based on positive hepatitis B surface antigen (HBsAg), positive antibody to hepatitis B core antigen (HBcAb), increased levels of ALT or aspartate aminotransferase (AST) for 6 or more months, and liver histological lesions compatible with chronic hepatitis B. In the 1980s and early 1990s, tests for HBsAg, anti-hepatitis B surface antibody (HBsAb), hepatitis B e antigen (HBeAg), and anti-hepatitis B e antibody (HBeAb) were provided routinely to patients for the diagnosis of HBV infection; HBV DNA was not used. Also, it was not possible to determine HBV genotypes. HBV DNA and HBV genotype were determined by using stored sera of the patients. HBV genotypes of stored samples were determined by complete genome sequencing. 27 A diagnosis of chronic hepatitis C was based on a positive result for anti-HCV antibody in fi rst or secondgeneration assays, presence of HCV RNA determined by reverse transcription-polymerase chain reaction, elevated serum ALT or AST levels for 6 or more months, and histological examination of liver biopsy specimens. Anti-HCV antibodies and HCV RNA were tested by using patients' sera stored since the 1980s or early 1990s.
Patients had been followed up by biochemical and hematological blood tests every 1 or 2 months. The changes in levels of white blood cells, platelets, albumin, total bilirubin, and total cholesterol, which correlate with histological progression and disease progression, were evaluated. The annual rates of change of these variables were calculated by dividing the change in the values of these variables between the tests at the fi rst and second biopsies by the interval in years between the biopsies.
Liver biopsy and histological examination
Once informed consent was obtained from each patient, peritoneoscopic liver biopsies were performed according to a standardized protocol. Biopsy specimens were fi xed in formalin, paraffi n-embedded, and stained with hematoxylin-eosin and azan and by reticulin silver impregnation. Specimens were reviewed by two experienced hepatopathologists who were blinded to the clinical characteristics and laboratory results of the study subjects.
The histology of liver biopsy specimens was evaluated for activity grade and fi brosis stage according to the criteria of Desmet et al. 10 and the French METAVIR Cooperative Study Group. 11, 12 The fi brosis stage was defi ned as F0 (no fi brosis), F1 (mild fi brosis), F2 (moderate fi brosis), F3 (severe fi brosis), or F4 (cirrhosis), and the activity grade was defi ned as A0 (no activity), A1 (mild activity), A2 (moderate activity), or A3 (severe activity). The fi brosis stages and activity grades of paired biopsy samples were compared; worsening and progression, or improvement and regression, were defi ned as an increase or decrease by 1 or more fi brosis stage or activity grade. The annual rate of fi brosis progression was calculated by dividing the change in fi brosis stage between the baseline and follow-up liver biopsies by the interval in years between them.
Statistical analysis
The descriptive statistics are given as median or mean values unless otherwise stated. Differences between groups were evaluated using the Wilcoxon signed-rank test or Welch's t test. Categorical variables were compared using the χ-squared test or Fisher's exact probability test. To identify the independent factors that affect the absence or presence of fi brosis progression, we performed univariate and multivariate logistic regression analyses on the clinical parameters.
A P value of less than 0.05 was considered statistically signifi cant. Statistical analyses were performed with JMP computer software, version 5.01J (SAS Institute, Cary, NC, USA) and StatView, version 5.0 (SAS Institute).
Results
Fibrosis progression in chronic hepatitis B
We evaluated 49 patients with chronic hepatitis B who had undergone two or more liver biopsies at an interval of more than 1 year. The median interval between the two biopsies was 3.4 (fi rst and third quartiles, 1.8-4.7) years. The clinical characteristics and demographics of the 49 patients at the time of each biopsy are shown in Table 1 . The HBV genotype was determined in 19 of 49 patients. All of the analyzed samples were found to be of genotype C, which is the dominant genotype in HBVinfected Japanese patients. 28 At the time of the fi rst biopsy, 44 patients with chronic hepatitis B were positive for HBeAg, and fi ve were negative. Of the 44 positive patients, six were negative at the second biopsy. All fi ve patients negative at the fi rst biopsy remained negative at the second. There were signifi cant differences in age (P < 0.001, Wilcoxon signed-rank test), distribution of fi brosis stage (P < 0.001), number of cases positive for HBeAg (P = 0.014), platelet count (P < 0.001), and total cholesterol level (P = 0.034) between the tests at the fi rst and second biopsies.
In the 49 patients with chronic hepatitis B, the fi brosis stage progressed in 27 (55.1%), did not change in 18 (36.7%), and regressed in four (8.2%) patients during the interval between biopsies (Table 2a) . The activity grade worsened in 16 (32.7%), did not change in 26 (53.0%), and improved in seven (14.3%) patients (Table 2b) . Overall, the rate of fi brosis progression was 0.21 ± 0.33 (mean ± SD) [95% confi dence interval (CI), 0.12-0.31] fi brosis units (FU) per year in the 49 patients with chronic hepatitis B. Particularly in patients who had undergone paired biopsies at a interval of 3 years or more, the mean fi brosis progression rate was 0.14 ± 0.20 (95% CI, 0.05-0.22) FU/year.
Among the 38 patients persistently positive for HBeAg during both biopsies, liver fi brosis progressed in 22 (57.9%) and did not change in 16 (42.1%). On the other hand, among the six patients who became negative for HBeAg between the two biopsies, the fi brosis stage progressed in three, did not change in one, and regressed in two patients. Of two patients who had normal ALT values after becoming HBe seronegative, the fi brosis stage regressed in one and did not change in one patient. Among patients who had continuously elevated ALT levels even after becoming HBe seronegative, the fi brosis stage progressed in three and regressed in one patient. Also, among the fi ve patients negative for HBeAg, fi brosis progressed in two, did not change in one, and regressed in two patients (Table 3) . These results suggested that the latter two groups involved patients who showed progression or regression of liver fi brosis.
Fibrosis progression in chronic hepatitis C
We evaluated 21 patients with chronic hepatitis C who had undergone paired biopsies at a median interval of 3.2 (2.1-6.5) years (Table 4 ). There were signifi cant differences in age (P < 0.001, Wilcoxon signed-rank test), distribution of fi brosis stage (P = 0.005), platelet count (P = 0.005), and albumin level (P = 0.031) between the tests at the fi rst and second biopsies.
At the second liver biopsy, compared with the fi rst, fi brosis stage had progressed in nine (42.9%) and did (Table  5b ). The rate of fi brosis progression in the 21 patients with chronic hepatitis C was 0.13 ± 0.18 FU/year (95% CI, 0.04-0.21). In particular, in patients who had undergone paired biopsies at a interval of 3 years and more, the mean fi brosis progression rate was 0.18 ± 0.18 (0.06-0.30) FU/year.
Factors affecting fi brosis progression
Factors infl uencing fi brosis progression were analyzed in all 70 patients with chronic hepatitis B or chronic hepatitis C. The 70 patients were classifi ed into a progression or nonprogression group according to the presence or absence of fi brosis progression, respectively. Thirty-six (chronic hepatitis B, 27; chronic hepatitis C, 9) patients whose fi brosis stage had progressed by one stage or more between biopsies were classifi ed into the progression group, and 34 (chronic hepatitis B, 22; chronic hepatitis C, 12) whose fi brosis stage had not changed or seemed to improve were stratifi ed into the nonprogression group. To identify variables capable of discriminating between these groups, logistic regression analyses were used, employing 14 variables: duration between biopsies, demographics (age, sex), viral factor (HBV vs. HCV), histological examinations (fi brosis stage, activity grade), hematological tests (white blood cell count, platelet count), and biochemical tests [albumin, total bilirubin, AST, ALT, LDH (lactate dehydrogenase), However, no correlation was found between HBV or HCV infection and liver fi brosis progression.
Fibrosis progression in terms of ALT level
From these results, ALT level was considered to be an independent variable correlating with liver fi brosis. For the analysis of annual progression rates in terms of elevated serum ALT levels, these 70 patients with chronic hepatitis B or chronic hepatitis C were stratifi ed into two groups according to their median ALT level measured every 3 months between biopsies; 26 patients had median ALT levels of less than 70 IU/l (double the normal upper limit, 35 IU/l) (chronic hepatitis B, 13; chronic hepatitis C, 13), and 44 patients had median ALT levels of 70 IU/l or more (chronic hepatitis B, 36; chronic hepatitis C, 8).
For the patients with median ALT levels less than 70 IU/l, the rate of fi brosis progression was 0.04 ± 0.31 FU/year (95% CI, −0.15 to 0.23) in patients with chronic hepatitis B and 0.07 ± 0.13 FU/year (−0.01 to 0.15) in patients with chronic hepatitis C ( Table 7) . This suggests that progression of liver fi brosis was minimal in patients with ALT levels of less than 70 IU/l. Also, there were no signifi cant differences in the annual rates of change of white blood cell count, platelet count, albumin, total bilirubin, or total cholesterol level between chronic hepatitis B and C patients.
For the patients with median ALT levels of 70 IU/l or more, the annual rate of fi brosis progression was 0.28 ± 0.32 FU/year (95% CI, 0.17 to 0.39) in chronic hepatitis B patients and 0.22 ± 0.23 FU/year (0.03 to 0.41) in chronic hepatitis C patients (Table 8 ). There was no signifi cant difference in the fi brosis progression rate between chronic hepatitis B and C patients (P = 0.562, and total cholesterol] at the time of the fi rst biopsy (Table 6 ). In a univariate analysis, we selected these variables: duration between biopsies, fi brosis stage, activity grade, platelet count, albumin level, and ALT level (the statistical level of signifi cance determined by log-rank test was set at P < 0.20). When these variables selected in the univariate analysis were evaluated in a multivariate analysis, the independent predictive factors discriminating between the two groups were albumin (P = 0.031, log-rank test), and ALT level (P = 0.032).
Welch's t test). Among patients with median ALT levels of 70 IU/l or more, there were no signifi cant differences in the annual change of white blood cell count, platelet count, total bilirubin, or cholesterol, whereas the annual rate of decrease in albumin in chronic hepatitis C patients was signifi cantly worse than that in chronic hepatitis B patients (P = 0.022, Welch's t test).
Discussion
In the present study, we evaluated the annual rate of fi brosis progression in 49 patients with chronic hepatitis B and 21 patients with chronic hepatitis C who had undergone paired biopsies at a median interval of 3.4 and 3.2 years, respectively. Fibrosis progression between the two biopsies was minimal in patients with an ALT level of less than 70 IU/l. In patients whose median ALT level was 70 IU/l or more, the rate of fi brosis progression was 0.28 ± 0.32 FU/year in patients with chronic hepatitis B, and 0.22 ± 0.23 FU/year in those with chronic hepatitis C. Considerable fi brosis progression occurred in patients with a continuously elevated ALT level even for a relatively short period: liver fi brosis could progress by one stage within the average of 4-5 years of followup in patients with elevated ALT.
On the basis of changes in fi brosis stages between paired biopsies in our patients with chronic hepatitis B or C, the present study demonstrated that progression of at least one stage occurred in a signifi cant proportion of chronic hepatitis B (27/49, 55.1%; median interval between biopsies, 3.4 years) and chronic hepatitis C (9/21, 42.9%; median interval, 3.2 years) patients between biopsies, even over a relatively short period. During the period between biopsies, the mean annual rate of fi brosis progression was 0.21 ± 0.33 FU/year in the overall 49 chronic hepatitis B patients and 0.13 ± 0.18 FU/year in 21 chronic hepatitis C patients. In a study by Papatheodoridis et al., 29 the change in the fi brosis score (estimated on a fi brosis staging scale of 0-6) between paired biopsies with a median interval of 25 (12-160) months indicated a mean annual rate of fi brosis progression of 0.427 ± 0.119 FU/year in untreated chronic hepatitis B patients, which was not too different from our estimate. In studies of fi brosis progression in chronic hepatitis C using the same system based on paired biopsies, the fi brosis progression rates have been reported to be 0.12 (estimated on a scale of 0-6), 23 0.10, 21 or 0.15 22 (estimated on a scale of 0-4) FU/year. These fi brosis progression rates in chronic hepatitis C are similar to our result, suggesting that, at these rates, cirrhosis would require an average of 30-40 years to develop if a linear rate of fi brosis progression is assumed from the nonfi brosis stage (F0) to the development of cirrhosis (F4). However, the assumption of a linear rate of progression is not necessarily valid. Especially, chronic HBV infection is a dynamic process with replicative, nonreplicative, or low-replicative phases that depend on virushost interactions. [24] [25] [26] The clinical course of chronic hepatitis B generally consists of three phases: immune tolerance, immune clearance with or without seroconversion from HBeAg to HBeAb, and residual (inactive carrier state) phases. [24] [25] [26] Because of the potential link between infl ammation activities and fi brosis, liver fi brosis in HBV-related liver injury might progress at inconsistent rates during its clinical course from infection to the development of cirrhosis. In the present study, we estimated the annual rate of fi brosis progression in established chronic hepatitis B on the basis of changes in the fi brosis stage between paired biopsies separated by a relatively short interval of 3-4 years. Therefore, the annual progression rates should be assigned to fi brosis progression only within the period of established chronic hepatitis and should not be applied to the entire clinical course from infection to the development of cirrhosis.
Among the clinical variables at the time of initial biopsy, ALT and albumin levels were correlated with subsequent fi brosis progression in patients with established chronic hepatitis B or C. However, HBV or HCV infection was not a signifi cant factor in fi brosis progression in our series. Several longitudinal analyses of patients with chronic hepatitis C have found that high ALT levels are associated with progression of fi brosis. 18, 23, 30 These data suggest that elevated ALT level in established chronic hepatitis is a useful predictor of hepatic fi brosis progression.
When patients with chronic hepatitis B or C were stratifi ed into two groups according to median ALT level measured every 3 months between biopsies, the annual rate of fi brosis progression differed markedly between patients with median values above or below 70 IU/L. Concerning fi brosis progression in terms of ALT levels, similar but not identical fi ndings were reported in a study of HBe-negative chronic hepatitis B patients treated with interferon-α, in which the annual rate of fi brosis progression was lower in a treated patient group, including patients with a sustained biochemical response (0.067 ± 0.052 FU/year) than in untreated patients (0.427 ± 0.119 FU/year). 29 Furthermore, in a study by Ghany et al., 23 the rate was <0.05 FU/year in a group of chronic hepatitis C patients with ALT levels <5 times the upper limit of normal. Similar fi ndings were recently reported in a longitudinal study of chronic hepatitis C patients with normal serum ALT levels (0.05 FU/year). 30 These data all suggest that in patients with minimal or no elevation in ALT levels, it is diffi cult to show any fi brosis progression, defi ned as an increase of at least one stage during a relatively short follow-up period of 3-5 years.
In chronic hepatitis B or C patients whose median ALT level was 70 IU/l or more between the two biopsies, the rate of fi brosis progression was 0.28 ± 0.32 and 0.22 ± 0.23 FU/year, respectively. Fibrosis progression occurred rapidly in patients with elevated ALT levels: liver fi brosis could progress by one stage within an average of 4-5 years of follow-up. In the present study, the fi ndings included the parametric estimate of liver fi brosis progression in chronic hepatitis B patients as compared with chronic hepatitis C patients and the lack of a difference in the rate of fi brosis progression during established chronic hepatitis between chronic hepatitis B and C. To date, no study has adequately compared the rate of fi brosis progression between chronic hepatitis B and C. The rate based on paired biopsies may be a better comparison method.
Some laboratory data, including albumin level and platelet count, are well-established variables associated with histological change and disease progression. 31, 32 To our knowledge, no previous studies have compared the changes in these variables between chronic hepatitis B and C. In our patients with elevated ALT levels, comparisons of the annual rates of changes in variables between chronic hepatitis B and C revealed that the rate of decrease in albumin level was signifi cantly worse in the latter even though there were no signifi cant differences in the rate of fi brosis progression or the rate of decrease in the platelet count. However, this fi nding needs to be validated in a large series of patients with HBV-or HCV-related chronic liver diseases.
Understanding the natural history and prognosis of chronic hepatitis B is the basis of disease management and the design of better therapeutic strategies. This paired-biopsy study in untreated chronic hepatitis B and C patients demonstrated that fi brosis progression occurred rapidly in patients with elevated ALT levels even over a relatively short period, and that liver fi brosis might progress by one stage within an average of 4-5 years of follow-up in patients with elevated ALT.
